Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 2.5mg/mL (2-mL or 4-mL, single-dose vial)
Postoperative Nausea & Vomiting
Prevention
- Indicated for prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class
- 5 mg as a single IV dose at time of anesthesia induction
Treatment
- Indicated for treatment of PONV in adults who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis
- 10 mg as a single IV dose in the event of nausea and/or vomiting postoperatively
Dosage Modifications
Renal impairment
- Mild-to-severe: No dosage adjustment necessary
- Pharmacokinetics changes following a single 5-mg or 10-mg IV dose are not considered to be clinically meaningful
Safety and efficacy not established
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (27)
- aripiprazole
amisulpride, aripiprazole. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- asenapine
amisulpride, asenapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- brexpiprazole
amisulpride, brexpiprazole. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- cariprazine
amisulpride, cariprazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- chlorpromazine
amisulpride, chlorpromazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- clozapine
amisulpride, clozapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.
- dronedarone
amisulpride and dronedarone both increase QTc interval. Contraindicated.
- droperidol
amisulpride, droperidol. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- fluphenazine
amisulpride, fluphenazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- haloperidol
amisulpride, haloperidol. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- iloperidone
amisulpride, iloperidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.
- loxapine
amisulpride, loxapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- loxapine inhaled
amisulpride, loxapine inhaled. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- lumateperone
amisulpride, lumateperone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- lurasidone
amisulpride, lurasidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- olanzapine
amisulpride, olanzapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.
- paliperidone
amisulpride, paliperidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- perphenazine
amisulpride, perphenazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- pimozide
amisulpride and pimozide both increase QTc interval. Contraindicated.
amisulpride, pimozide. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome. - prochlorperazine
amisulpride, prochlorperazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- quetiapine
amisulpride, quetiapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.
- risperidone
amisulpride, risperidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- thalidomide
amisulpride and thalidomide both increase sedation. Contraindicated.
- thioridazine
amisulpride and thioridazine both increase QTc interval. Contraindicated.
amisulpride, thioridazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome. - thiothixene
amisulpride, thiothixene. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- trifluoperazine
amisulpride, trifluoperazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- ziprasidone
amisulpride, ziprasidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.
Serious - Use Alternative (172)
- acrivastine
amisulpride and acrivastine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- alfentanil
amisulpride and alfentanil both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- alfuzosin
amisulpride and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- amantadine
amisulpride, amantadine. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- amiodarone
amiodarone and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- anagrelide
anagrelide and amisulpride both increase QTc interval. Avoid or Use Alternate Drug.
- apomorphine
amisulpride, apomorphine. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
apomorphine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered. - arformoterol
arformoterol and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- aripiprazole
aripiprazole and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- arsenic trioxide
amisulpride and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- artemether
artemether and amisulpride both increase QTc interval. Avoid or Use Alternate Drug.
- artemether/lumefantrine
amisulpride and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- asenapine
amisulpride and asenapine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- asenapine transdermal
asenapine transdermal and amisulpride both increase QTc interval. Avoid or Use Alternate Drug.
- atomoxetine
atomoxetine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- azithromycin
amisulpride and azithromycin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- bedaquiline
amisulpride and bedaquiline both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- benzhydrocodone/acetaminophen
amisulpride and benzhydrocodone/acetaminophen both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- bromocriptine
amisulpride, bromocriptine. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- buprenorphine
amisulpride and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
amisulpride and buprenorphine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate - buprenorphine buccal
buprenorphine buccal and amisulpride both increase QTc interval. Avoid or Use Alternate Drug.
amisulpride and buprenorphine buccal both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate - buprenorphine subdermal implant
buprenorphine subdermal implant and amisulpride both increase QTc interval. Avoid or Use Alternate Drug.
amisulpride and buprenorphine subdermal implant both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate - buprenorphine transdermal
buprenorphine transdermal and amisulpride both increase QTc interval. Avoid or Use Alternate Drug.
amisulpride and buprenorphine transdermal both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate - buprenorphine, long-acting injection
buprenorphine, long-acting injection and amisulpride both increase QTc interval. Avoid or Use Alternate Drug.
amisulpride and buprenorphine, long-acting injection both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate - ceritinib
ceritinib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- chloroquine
chloroquine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- chlorpromazine
chlorpromazine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ciprofloxacin
amisulpride and ciprofloxacin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- citalopram
citalopram and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- clarithromycin
clarithromycin and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- clozapine
clozapine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- codeine
amisulpride and codeine both increase sedation. Avoid or Use Alternate Drug.
- crizotinib
crizotinib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- dasatinib
dasatinib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- degarelix
degarelix and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- desflurane
desflurane and amisulpride both increase QTc interval. Avoid or Use Alternate Drug.
amisulpride and desflurane both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered. - disopyramide
amisulpride and disopyramide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- dofetilide
amisulpride and dofetilide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- dolasetron
amisulpride and dolasetron both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- donepezil
donepezil and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- droperidol
amisulpride and droperidol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- efavirenz
efavirenz and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- eliglustat
amisulpride and eliglustat both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- encorafenib
encorafenib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- entrectinib
entrectinib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- eribulin
eribulin and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- erythromycin base
amisulpride and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- erythromycin ethylsuccinate
amisulpride and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- erythromycin lactobionate
amisulpride and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- erythromycin stearate
amisulpride and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- escitalopram
amisulpride and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- fenoldopam
amisulpride, fenoldopam. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- fentanyl
amisulpride and fentanyl both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- fentanyl intranasal
amisulpride and fentanyl intranasal both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- fentanyl iontophoretic transdermal system
amisulpride and fentanyl iontophoretic transdermal system both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- fentanyl transdermal
amisulpride and fentanyl transdermal both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- fentanyl transmucosal
amisulpride and fentanyl transmucosal both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- fexinidazole
amisulpride and fexinidazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- fingolimod
fingolimod and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- flecainide
amisulpride and flecainide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- fluconazole
amisulpride and fluconazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- fluoxetine
amisulpride and fluoxetine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- fluvoxamine
amisulpride and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- formoterol
amisulpride and formoterol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- foscarnet
amisulpride and foscarnet both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- fostemsavir
amisulpride and fostemsavir both increase QTc interval. Avoid or Use Alternate Drug. QTc prolongation reported with higher than recommended doses of fostemsavir.
- gemifloxacin
gemifloxacin and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- gemtuzumab
amisulpride and gemtuzumab both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- gilteritinib
amisulpride and gilteritinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- glasdegib
amisulpride and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- goserelin
amisulpride and goserelin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- granisetron
amisulpride and granisetron both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- haloperidol
amisulpride and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- histrelin
amisulpride and histrelin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- hydrocodone
amisulpride and hydrocodone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- hydromorphone
amisulpride and hydromorphone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- hydroxychloroquine sulfate
amisulpride and hydroxychloroquine sulfate both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- hydroxyzine
amisulpride and hydroxyzine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ibutilide
amisulpride and ibutilide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- iloperidone
amisulpride and iloperidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- indacaterol, inhaled
amisulpride and indacaterol, inhaled both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- inotuzumab
amisulpride and inotuzumab both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- isoflurane
amisulpride and isoflurane both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- itraconazole
amisulpride and itraconazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ivosidenib
amisulpride and ivosidenib both decrease QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- lapatinib
amisulpride and lapatinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- lefamulin
amisulpride and lefamulin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- lenvatinib
amisulpride and lenvatinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- leuprolide
amisulpride and leuprolide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- levalbuterol
amisulpride and levalbuterol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- levodopa
amisulpride, levodopa. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- levodopa inhaled
amisulpride, levodopa inhaled. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- levofloxacin
amisulpride and levofloxacin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- levoketoconazole
amisulpride and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.
- lithium
amisulpride and lithium both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
lithium and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. - lofexidine
amisulpride and lofexidine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- loperamide
amisulpride and loperamide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- lopinavir
amisulpride and lopinavir both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- macimorelin
amisulpride and macimorelin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- maprotiline
maprotiline and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- mefloquine
amisulpride and mefloquine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- methadone
amisulpride and methadone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
amisulpride and methadone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate - midostaurin
amisulpride and midostaurin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- mifepristone
amisulpride and mifepristone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- mirtazapine
amisulpride and mirtazapine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- mobocertinib
amisulpride and mobocertinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- morphine
amisulpride and morphine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- moxifloxacin
amisulpride and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- nilotinib
amisulpride and nilotinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- octreotide
amisulpride and octreotide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- octreotide (Antidote)
amisulpride and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ofloxacin
amisulpride and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- olanzapine
amisulpride and olanzapine both increase QTc interval. Avoid or Use Alternate Drug. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instances
- olodaterol inhaled
amisulpride and olodaterol inhaled both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ondansetron
amisulpride and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- osilodrostat
amisulpride and osilodrostat both increase QTc interval. Avoid or Use Alternate Drug. Dose dependent QT prolongation - avoid drugs known to prolong the QT interval
- osimertinib
amisulpride and osimertinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- oxaliplatin
amisulpride and oxaliplatin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- oxycodone
amisulpride and oxycodone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- oxymorphone
amisulpride and oxymorphone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- ozanimod
amisulpride and ozanimod both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- paliperidone
amisulpride and paliperidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- panobinostat
amisulpride and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- pasireotide
amisulpride and pasireotide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- pazopanib
amisulpride and pazopanib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- pentamidine
amisulpride and pentamidine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- perphenazine
perphenazine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- pimavanserin
amisulpride and pimavanserin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- pitolisant
amisulpride and pitolisant both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ponesimod
amisulpride and ponesimod both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- posaconazole
amisulpride and posaconazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- pramipexole
amisulpride, pramipexole. Either decreases effects of the other by pharmacodynamic antagonism. Contraindicated. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- primaquine
amisulpride and primaquine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- procainamide
amisulpride and procainamide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- promethazine
promethazine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- propafenone
amisulpride and propafenone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- quetiapine
amisulpride and quetiapine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- quinidine
quinidine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- quinine
amisulpride and quinine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ranolazine
amisulpride and ranolazine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- rilpivirine
amisulpride and rilpivirine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- risperidone
amisulpride and risperidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- romidepsin
amisulpride and romidepsin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ropinirole
amisulpride, ropinirole. Either decreases effects of the other by pharmacodynamic antagonism. Contraindicated. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- rotigotine
amisulpride, rotigotine. Either decreases effects of the other by pharmacodynamic antagonism. Contraindicated. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- salmeterol
amisulpride and salmeterol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- saquinavir
amisulpride and saquinavir both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- selpercatinib
amisulpride and selpercatinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- sertraline
amisulpride and sertraline both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- sevoflurane
amisulpride and sevoflurane both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- siponimod
amisulpride and siponimod both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- sorafenib
amisulpride and sorafenib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- sotalol
amisulpride and sotalol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- sunitinib
amisulpride and sunitinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- tacrolimus
amisulpride and tacrolimus both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- tapentadol
amisulpride and tapentadol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- tetrabenazine
amisulpride and tetrabenazine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- toremifene
amisulpride and toremifene both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- tramadol
amisulpride and tramadol both increase sedation. Avoid or Use Alternate Drug.
- trazodone
trazodone and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- triazolam
amisulpride and triazolam both increase sedation. Avoid or Use Alternate Drug.
- triclabendazole
amisulpride and triclabendazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- triptorelin
amisulpride and triptorelin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- umeclidinium bromide/vilanterol inhaled
amisulpride and umeclidinium bromide/vilanterol inhaled both decrease QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- vandetanib
amisulpride and vandetanib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- vardenafil
amisulpride and vardenafil both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- vemurafenib
amisulpride and vemurafenib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- venlafaxine
amisulpride and venlafaxine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- vilanterol/fluticasone furoate inhaled
amisulpride and vilanterol/fluticasone furoate inhaled both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- voclosporin
amisulpride and voclosporin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- vorinostat
amisulpride and vorinostat both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- ziprasidone
amisulpride and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
Monitor Closely (145)
- acetaminophen/phenyltoloxamine
amisulpride and acetaminophen/phenyltoloxamine both increase sedation. Use Caution/Monitor.
- acrivastine
acrivastine and amisulpride both increase sedation. Use Caution/Monitor.
- albuterol
albuterol and amisulpride both increase QTc interval. Use Caution/Monitor.
amisulpride and albuterol both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered. - alprazolam
amisulpride and alprazolam both increase sedation. Use Caution/Monitor.
- amitriptyline
amitriptyline and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
amisulpride and amitriptyline both increase sedation. Use Caution/Monitor.
amisulpride and amitriptyline both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered. - amobarbital
amisulpride and amobarbital both increase sedation. Use Caution/Monitor.
- amoxapine
amisulpride and amoxapine both increase sedation. Use Caution/Monitor.
- asenapine
amisulpride and asenapine both increase sedation. Use Caution/Monitor.
- asenapine transdermal
amisulpride and asenapine transdermal both increase sedation. Use Caution/Monitor.
- avapritinib
amisulpride and avapritinib both increase sedation. Use Caution/Monitor.
- baclofen
amisulpride and baclofen both increase sedation. Use Caution/Monitor.
- brexanolone
amisulpride and brexanolone both increase sedation. Use Caution/Monitor.
- brexpiprazole
amisulpride and brexpiprazole both increase sedation. Use Caution/Monitor.
- brimonidine
amisulpride and brimonidine both increase sedation. Use Caution/Monitor.
- brivaracetam
amisulpride and brivaracetam both increase sedation. Use Caution/Monitor.
- brompheniramine
amisulpride and brompheniramine both increase sedation. Use Caution/Monitor.
- buprenorphine subdermal implant
buprenorphine subdermal implant and amisulpride both increase sedation. Use Caution/Monitor.
- butabarbital
amisulpride and butabarbital both increase sedation. Use Caution/Monitor.
- butalbital
amisulpride and butalbital both increase sedation. Use Caution/Monitor.
- butorphanol
amisulpride and butorphanol both increase sedation. Use Caution/Monitor.
- carbinoxamine
amisulpride and carbinoxamine both increase sedation. Use Caution/Monitor.
- cariprazine
amisulpride and cariprazine both increase sedation. Use Caution/Monitor.
- carisoprodol
amisulpride and carisoprodol both increase sedation. Use Caution/Monitor.
- cenobamate
amisulpride and cenobamate both increase sedation. Use Caution/Monitor.
- cetirizine
amisulpride and cetirizine both increase sedation. Use Caution/Monitor.
- chlordiazepoxide
amisulpride and chlordiazepoxide both increase sedation. Use Caution/Monitor.
- chlorpheniramine
amisulpride and chlorpheniramine both increase sedation. Use Caution/Monitor.
- chlorzoxazone
amisulpride and chlorzoxazone both increase sedation. Use Caution/Monitor.
- clemastine
amisulpride and clemastine both increase sedation. Use Caution/Monitor.
- clobazam
amisulpride and clobazam both increase sedation. Use Caution/Monitor.
- clofazimine
amisulpride and clofazimine both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- clomipramine
clomipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- clonazepam
amisulpride and clonazepam both increase sedation. Use Caution/Monitor.
- clonidine
amisulpride and clonidine both increase sedation. Use Caution/Monitor.
- clorazepate
amisulpride and clorazepate both increase sedation. Use Caution/Monitor.
- cyclobenzaprine
amisulpride and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- cyproheptadine
amisulpride and cyproheptadine both increase sedation. Use Caution/Monitor.
- dantrolene
amisulpride and dantrolene both increase sedation. Use Caution/Monitor.
- daridorexant
amisulpride and daridorexant both increase sedation. Use Caution/Monitor.
- desflurane
amisulpride and desflurane both increase sedation. Use Caution/Monitor.
- desipramine
desipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
amisulpride and desipramine both increase sedation. Use Caution/Monitor. - deutetrabenazine
deutetrabenazine and amisulpride both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).
amisulpride and deutetrabenazine both increase sedation. Use Caution/Monitor. - dexbrompheniramine
amisulpride and dexbrompheniramine both increase sedation. Use Caution/Monitor.
- dexchlorpheniramine
amisulpride and dexchlorpheniramine both increase sedation. Use Caution/Monitor.
- diazepam
amisulpride and diazepam both increase sedation. Use Caution/Monitor.
- difenoxin hcl
amisulpride and difenoxin hcl both increase sedation. Use Caution/Monitor.
- dimenhydrinate
amisulpride and dimenhydrinate both increase sedation. Use Caution/Monitor.
- diphenhydramine
amisulpride and diphenhydramine both increase sedation. Use Caution/Monitor.
- diphenoxylate hcl
amisulpride and diphenoxylate hcl both increase sedation. Use Caution/Monitor.
- doxepin
doxepin and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- doxylamine
amisulpride and doxylamine both increase sedation. Use Caution/Monitor.
- efavirenz
amisulpride and efavirenz both increase sedation. Use Caution/Monitor.
- entacapone
amisulpride and entacapone both increase sedation. Use Caution/Monitor.
- esketamine intranasal
amisulpride and esketamine intranasal both increase sedation. Use Caution/Monitor.
- estazolam
amisulpride and estazolam both increase sedation. Use Caution/Monitor.
- eszopiclone
amisulpride and eszopiclone both increase sedation. Use Caution/Monitor.
- ethosuximide
amisulpride and ethosuximide both increase sedation. Use Caution/Monitor.
- ethotoin
amisulpride and ethotoin both increase sedation. Use Caution/Monitor.
- ezogabine
amisulpride and ezogabine both increase QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed, particularly when dose titrated to 1200mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.
- felbamate
amisulpride and felbamate both increase sedation. Use Caution/Monitor.
- fexofenadine
amisulpride and fexofenadine both increase sedation. Use Caution/Monitor.
- flibanserin
amisulpride and flibanserin both increase sedation. Use Caution/Monitor.
- fluphenazine
fluphenazine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- flurazepam
amisulpride and flurazepam both increase sedation. Use Caution/Monitor.
- gabapentin
amisulpride and gabapentin both increase sedation. Use Caution/Monitor.
- gadobenate
gadobenate and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- ganaxolone
amisulpride and ganaxolone both increase sedation. Use Caution/Monitor.
- guanfacine
amisulpride and guanfacine both increase sedation. Use Caution/Monitor.
- hydroxyzine
amisulpride and hydroxyzine both increase sedation. Use Caution/Monitor.
- imipramine
imipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- indapamide
amisulpride and indapamide both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- isoflurane
amisulpride and isoflurane both increase sedation. Use Caution/Monitor.
- ketamine
amisulpride and ketamine both increase sedation. Use Caution/Monitor.
- ketotifen, drug-eluting contact lens
amisulpride and ketotifen, drug-eluting contact lens both increase sedation. Use Caution/Monitor.
- lamotrigine
amisulpride and lamotrigine both increase sedation. Use Caution/Monitor.
- lasmiditan
amisulpride and lasmiditan both increase sedation. Use Caution/Monitor.
- lemborexant
amisulpride and lemborexant both increase sedation. Use Caution/Monitor.
- levetiracetam
amisulpride and levetiracetam both increase sedation. Use Caution/Monitor.
- levocetirizine
amisulpride and levocetirizine both increase sedation. Use Caution/Monitor.
- levorphanol
amisulpride and levorphanol both increase sedation. Use Caution/Monitor.
- loratadine
amisulpride and loratadine both increase sedation. Use Caution/Monitor.
- lorazepam
amisulpride and lorazepam both increase sedation. Use Caution/Monitor.
- lumateperone
amisulpride and lumateperone both increase sedation. Use Caution/Monitor.
- lurasidone
amisulpride and lurasidone both increase sedation. Use Caution/Monitor.
- meclizine
amisulpride and meclizine both increase sedation. Use Caution/Monitor.
- meperidine
amisulpride and meperidine both increase sedation. Use Caution/Monitor.
- metaxalone
amisulpride and metaxalone both increase sedation. Use Caution/Monitor.
- methocarbamol
amisulpride and methocarbamol both increase sedation. Use Caution/Monitor.
- methohexital
amisulpride and methohexital both increase sedation. Use Caution/Monitor.
- methsuximide
amisulpride and methsuximide both increase sedation. Use Caution/Monitor.
- midazolam
amisulpride and midazolam both increase sedation. Use Caution/Monitor.
- molindone
amisulpride and molindone both increase sedation. Use Caution/Monitor.
- nalbuphine
amisulpride and nalbuphine both increase sedation. Use Caution/Monitor.
- nitrous oxide
amisulpride and nitrous oxide both increase sedation. Use Caution/Monitor.
- nortriptyline
nortriptyline and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
amisulpride and nortriptyline both increase sedation. Use Caution/Monitor. - oliceridine
amisulpride and oliceridine both increase sedation. Use Caution/Monitor.
- olopatadine intranasal
amisulpride and olopatadine intranasal both increase sedation. Use Caution/Monitor.
- opicapone
amisulpride and opicapone both increase sedation. Use Caution/Monitor.
- opium tincture
amisulpride and opium tincture both increase sedation. Use Caution/Monitor.
- orphenadrine
amisulpride and orphenadrine both increase sedation. Use Caution/Monitor.
- osilodrostat
osilodrostat and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- oxazepam
amisulpride and oxazepam both increase sedation. Use Caution/Monitor.
- pentazocine
amisulpride and pentazocine both increase sedation. Use Caution/Monitor.
- pentobarbital
amisulpride and pentobarbital both increase sedation. Use Caution/Monitor.
- perampanel
amisulpride and perampanel both increase sedation. Use Caution/Monitor.
- pheniramine
amisulpride and pheniramine both increase sedation. Use Caution/Monitor.
- phenobarbital
amisulpride and phenobarbital both increase sedation. Use Caution/Monitor.
- phenylephrine PO
amisulpride increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pomalidomide
amisulpride and pomalidomide both increase sedation. Use Caution/Monitor.
- pregabalin
amisulpride and pregabalin both increase sedation. Use Caution/Monitor.
- primidone
amisulpride and primidone both increase sedation. Use Caution/Monitor.
- prochlorperazine
prochlorperazine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- promethazine
amisulpride and promethazine both increase sedation. Use Caution/Monitor.
- propofol
amisulpride and propofol both increase sedation. Use Caution/Monitor.
- protriptyline
protriptyline and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- pyrilamine
amisulpride and pyrilamine both increase sedation. Use Caution/Monitor.
- quazepam
amisulpride and quazepam both increase sedation. Use Caution/Monitor.
- remifentanil
amisulpride and remifentanil both increase sedation. Use Caution/Monitor.
- remimazolam
amisulpride and remimazolam both increase sedation. Use Caution/Monitor.
- reserpine
amisulpride and reserpine both increase sedation. Use Caution/Monitor.
- scopolamine
amisulpride and scopolamine both increase sedation. Use Caution/Monitor.
- sevoflurane
amisulpride and sevoflurane both increase sedation. Use Caution/Monitor.
- sodium oxybate
amisulpride and sodium oxybate both increase sedation. Use Caution/Monitor.
- solifenacin
amisulpride and solifenacin both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- stiripentol
amisulpride and stiripentol both increase sedation. Use Caution/Monitor.
- sufentanil
amisulpride and sufentanil both increase sedation. Use Caution/Monitor.
- sufentanil SL
amisulpride and sufentanil SL both increase sedation. Use Caution/Monitor.
- suvorexant
amisulpride and suvorexant both increase sedation. Use Caution/Monitor.
- tasimelteon
amisulpride and tasimelteon both increase sedation. Use Caution/Monitor.
- telavancin
amisulpride and telavancin both increase QTc interval. Modify Therapy/Monitor Closely. ECG monitoring is recommended if coadministered.
- temazepam
amisulpride and temazepam both increase sedation. Use Caution/Monitor.
- tetrabenazine
amisulpride and tetrabenazine both increase sedation. Use Caution/Monitor.
- tiagabine
amisulpride and tiagabine both increase sedation. Use Caution/Monitor.
- tizanidine
amisulpride and tizanidine both increase sedation. Use Caution/Monitor.
- tolcapone
amisulpride and tolcapone both increase sedation. Use Caution/Monitor.
- trazodone
amisulpride and trazodone both increase sedation. Use Caution/Monitor.
- trifluoperazine
trifluoperazine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- trimipramine
trimipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- triprolidine
amisulpride and triprolidine both increase sedation. Use Caution/Monitor.
- valbenazine
valbenazine and amisulpride both increase QTc interval. Use Caution/Monitor.
- valproic acid
amisulpride and valproic acid both increase sedation. Use Caution/Monitor.
- vigabatrin
amisulpride and vigabatrin both increase sedation. Use Caution/Monitor.
- zaleplon
amisulpride and zaleplon both increase sedation. Use Caution/Monitor.
- zolpidem
amisulpride and zolpidem both increase sedation. Use Caution/Monitor.
- zonisamide
amisulpride and zonisamide both increase sedation. Use Caution/Monitor.
Minor (0)
Adverse Effects
1-10%
Prevention of PONV
- Increased blood prolactin (5%)
- Chills (4%)
- Hypokalemia (4%)
- Procedural hypotension (3%)
- Abdominal distension (2%)
Treatment of PONV
- Infusion site pain (6%)
Postmarketing Reports
Blood and lymphatic system disorders: Agranulocytosis
Cardiac disorders: Bradycardia, torsades de pointes, ventricular tachycardia, prolonged QT by ECG
General disorders: Neuroleptic malignant syndrome
Immune system disorders: Angioedema, hypersensitivity, urticaria
Hepatic disorders: Increased hepatic enzymes
Nervous system disorders: Agitation, anxiety, dystonia, extrapyramidal disorder, seizure
Psychiatric disorders: Confusional state, insomnia, somnolence
Vascular disorders: Hypotension
Warnings
Contraindications
Hypersensitivity
Cautions
QT prolongation
- May causes dose- and concentration-dependent prolongation of the QT interval
- Avoid in patients with congenital long QT syndrome and in patients taking droperidol
- ECG monitoring recommended with preexisting arrhythmias/cardiac conduction disorders, electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), congestive heart failure, and in patients taking other drugs (eg, ondansetron) or with other medical conditions known to prolong the QT interval
Drug interactions overview
- Amisulpride inhibits MATE1 and MATE2-K transporters
- Amisulpride is a substrate for P-gp, BCRP, OCT1, MATE1, and MATE2-K
-
Dopamine agonists
- Reciprocal antagonism of effects occurs between dopamine agonists (eg, levodopa)
- Avoid use
-
Drugs prolonging the QT interval
- Amisulpride causes dose- and concentration-dependent QT prolongation
- Avoid use with droperidol
- ECG monitoring recommended if coadministered with other drugs known to prolong QT interval (eg, ondansetron)
Pregnancy & Lactation
Pregnancy
Insufficient data available regarding use in pregnant women to establish a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes
Infertility
- In animal fertility studies, administration of repeated doses of amisulpride over a 10-day period to female rats resulted in infertility that was reversible
Lactation
Based on case reports in published literature, amisulpride is present in human milk at concentrations that are 11- to 20-fold higher than human plasma in patients taking multiple oral doses of amisulpride (200-400 mg/day)
There are no reports of adverse effects on breastfed children and no information on effects of amisulpride on milk production
May consider interrupting breastfeeding and pumping and discarding breast milk for 48 hr after administration to minimize drug exposure to a breastfed infant
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist
D2 receptors are located in the chemoreceptor trigger zone (CTZ) and respond to the dopamine released from the nerve endings
Activation of CTZ relays stimuli to the vomiting center, which is involved in emesis
Absorption
Peak plasma concentration
- Healthy subjects: 200 ng/mL (5 mg); 451 ng/mL (10 mg)
- Patients: 58-64 ng/mL (5 mg); 446 ng/mL (10 mg)
AUC
- Healthy subjects: 154 ng⋅hr/mL (5 mg); 136 ng⋅hr/mL (10 mg)
- Patients: 204-260 ng⋅hr/mL (5 mg); 401 ng⋅hr/mL (10 mg)
Distribution
Vd: 127-144 L (surgical patients); 171 L (healthy subjects)
Protein bound: 25-30%
Metabolism
No metabolites were detectable in plasma while 4 metabolites were identified in urine and feces
Each metabolite accounts for <7% of the dose
In vitro amisulpride is not metabolized by major cytochrome P450 enzymes
Elimination
Half-life: ~ 4-5 hr
Clearance: 20.6 hr (surgical patients); 24.1 L/hr (healthy subjects)
Renal clearance: 20.5 L/hr (healthy subjects)
Excretion: Urine (74% [58% unchanged]), feces (23% [20% unchanged])
Administration
IV Compatibilities
Sterile water for injection
Dextrose 5% (D5W)
0.9% NaCl
Lactated Ringer (LR)
IV Administration
Dilution not required
Infuse over 1-2 min
May flush IV line before or after administration with sterile water for injection, D5W, LR, or 0.9% NaCl
Storage
Protect from light
Unopened vials: Store at 20-25ºC (68-77ºF)
Open vials: Administer within 12 hr of removal of the vial from the protective carton
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
